Share This Author
International consensus guidance for management of myasthenia gravis
An international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide is developed.
Mechanical model of brain convolutional development.
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled,…
A genome-wide association study of myasthenia gravis.
The genetic data provide insights into aberrant cellular mechanisms responsible for this prototypical autoimmune disorder and suggest that clinical trials of immunomodulatory drugs related to CTLA4 and that are already Food and Drug Administration approved as therapies for other autoimmune diseases could be considered for patients with refractory disease.
Neuromuscular transmission in amyotrophic lateral sclerosis
The functional and structural characteristics of the neuromuscular junction were studied in anconeus muscle biopsies of 10 patients with amyotrophic lateral sclerosis (ALS) and decreased amplitudes of miniature endplate potentials (MEPPs) revealed.
An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis
Initiation of mycophenolate mofetil treatment was not superior to placebo in maintaining myasthenia gravis control during a 36-week schedule of prednisone tapering, but MMF was well tolerated and adverse events were consistent with previous studies.
Treatment of autoimmune myasthenia gravis
Immune-directed treatment of patients with MG is aimed at inducing an immunologic remission and then maintaining that remission, usually accomplished by slow tapering of the corticosteroids along with the use of “steroid-sparing” agents, which include azathioprine, thymectomy, and possibly mycophenolate.
Treatment of Myasthenia Gravis Based on Its Immunopathogenesis
The prognosis of myasthenia gravis has improved dramatically due to advances in critical-care medicine and symptomatic treatments, but the treatment of MG has been based primarily on experience rather than gold-standard evidence from randomized controlled trials.
Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.
Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.
Findings support the role of MuSK antibodies in the human disease, demonstrate the roleof MuSK not only in the development of the NMJ but also in the maintenance of the mature synapse, and demonstrate involvement of this disease in both presynaptic and postsynaptic components of theNMJ.